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1. Introduction 
The treatment of multiple sclerosis (MS) is entering a new era, characterized by the 
availability of a broad range of disease modifying drugs (DMDs) for patients in the 
relapsing-remitting (RR) phase of the disease. Through interference with immune-
mediated inflammatory processes the DMDs reduce the number and severity of relapses 
and the increase in relapse-related disability. Each DMD is characterized by a unique 
combination of mode of action, route of administration, degree of efficacy and potential 
side effects. In the past two decades the injectable drugs interferon beta-1a (INFb-1a), 
INFb-1b and glatiramer acetate (GA) have been proven to be safe first-line treatments. In 
more recent years, the intravenously administered monoclonal antibody natalizumab and 
the oral drugs fingolimod and cladribine have been demonstrated to be efficacious in 
RRMS. These DMDs are more potent, but also potentially more hazardous, which by and 
large restricts their use to patients who have very active disease or are refractory to first-
line treatment. Lately, phase II/III studies showed beneficial effects of the oral drugs 
teriflunomide, laquinimod and BG-12, and the monoclonal antibodies rituximab and 
alemtuzumab in RRMS.   
The advent of the new treatments coincides with the Web 2.0 evolution of the internet 
technology. Web 2.0 offers patients, doctors, and nurses unforeseen possibilities to 
fundamentally change, and hopefully improve, the ways in which care is delivered and 
clinical, patient-centered research is performed. The term Web 2.0 is associated with web 
applications that facilitate participatory information sharing, inter-operability, user-centered 
design and collaboration on the World Wide Web [1]. A Web 2.0 site allows users to interact 
and collaborate with each other, e.g. as creators of user-generated content in a virtual 
community, in contrast to websites where users are limited to the passive viewing 
of content that was created for them [2].  
Basically, e-health 2.0 can be defined as the merging of the Web 2.0 phenomenon within 
health care [3]. However, e-health 2.0 goes beyond the social networking technology to 
include a reformative or even revolutionary change in the fields of health care and clinical 
research [3]. According to O’Grady the main point of e-health 2.0 is the use of social 
software and its ability to promote collaboration between patients, their caregivers, and 
medical professionals [3]. Thus, using the web to exchange information with others 
substantially relates to learning and education about an illness, what treatment options are 
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available, how to make decisions, and for support [3]. In a broad sense, it can be conceived 
that Web 2.0 technologies enable and facilitate social networking, participation, openness, 
and collaboration, within and between health care consumers, caregivers, patients, health 
professionals, and biomedical researchers [4]. 
This chapter highlights actual developments at the crossroads of MS treatment and research 
and interactive applications of the internet, thereby focusing on online self-assessment, 
interactive web-based care and interactive phase IV research, and their potential for patient 
empowerment.       
2. Multiple sclerosis 
2.1 Disease characteristics 
MS is a chronic disease of the central nervous system (CNS) that is pathologically 
characterized by multiple areas of inflammation, demyelination, axonal loss and gliosis, 
predominantly but not exclusively in the white matter. Compared to other chronic CNS 
disorders MS is distinguished by a wide range of symptoms and a highly variable course. 
Typical clinical features are optic neuritis, paresis, diplopia, paresthesias, incoordination, 
bladder and bowel disturbances, cognitive dysfunction, anxiety, depression and fatigue [5].   
In most patients the onset of disease is between 20 and 40 years of age. In 80% to 85% of the 
patients the initial phase is characterized by relapses and remissions: RRMS. Relapse / 
remission episodes are alternated by relatively stable periods of months to years. During a 
relapse symptoms typically evolve over days to weeks, and after a plateau phase often 
spontaneously improve, completely or incompletely. The total duration of a relapse / 
remission episode, from initial symptom to final recovery, varies from less than a week to 
more than half a year.  
To explain the etiology of MS it is thought that myelin-specific auto-reactive lymphocytes 
are primed in the periphery by unknown factors, after which they migrate to the CNS, 
leading to inflammatory demyelination and axonal loss [6]. Recent studies have suggested 
that the innate immune system also plays a role both in the initiation and progression of MS 
[6]. Inflammation composed of mononuclear cells, breakdown of the blood brain barrier, 
focal plaques of demyelination and axonal damage characterize the acute MS lesions and 
underlie relapses [7]. Importantly, the frequency and severity of the immune-mediated 
changes can be reduced by DMDs.   
As the disease duration increases the tendency of relapses to recover diminishes, which 
results in a higher risk of relapse-related deficits and a step-wise accrual of disability. 
Eventually, after a period of 10 to 20 years, most RRMS patients transgress to the secondary 
progressive phase (SPMS), characterized by a relentless continuous progression of disability. 
In about 15% of the MS patients symptoms start insidiously and continue to slowly progress 
without relapses, the primary progressive course (PPMS). In both SPMS and PPMS clinical 
deficits mainly result from axonal degeneration, whereas inflammation plays only a minor 
role. Accordingly, DMDs are not efficacious in SPMS and PPMS.    
2.2 Diagnosis 
In the last two decades the sensitivity and specificity of the MS diagnosis has considerably 
improved due to two developments. Firstly, the wide-spread use of the magnetic resonance 
imaging (MRI) technique for detection of lesions in brain and spinal cord, and secondly, 
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new diagnostic criteria proposed by McDonald et al.. The improved diagnosis in 
combination with the availability of DMDs has increased doctors’ awareness of MS as a 
possible cause of an episode of CNS disturbances in young adults. In such patients ancillary 
MRI and cerebrospinal fluid (CSF) analyses may yield abnormal findings that, in 
combination with the clinical features, justify the diagnosis possible or definite RRMS 
according to the revised McDonald criteria [8]. Patients who do not fulfill these criteria and 
in whom other disorders have been adequately excluded are diagnosed as having a so-
called clinically isolated syndrome (CIS) suggestive of MS, briefly CIS [8]. A CIS may be 
monofocal – when clinical abnormalities relate to a single CNS lesion – or multifocal, and 
often involve the optic nerve, brainstem, cerebellum, spinal cord, or cerebral hemispheres 
[8].   
On T2-weighed brain MRI the great majority of MS patients show multiple hyper-intense 
lesions. These are typically ovoid shaped with the longitudinal axis perpendicular to the 
ventricles, of varying hyper-intensity, and located peri-ventricular, juxta-cortical or infra-
tentorial in an asymmetric bilateral pattern [8]. In most MS patients MRI of the spinal cord 
also shows T2 hyper-intense abnormalities, and the absence of spinal lesions on a technically 
adequate MRI scan is considered a red flag.   
2.3 Assessment and treatment of major symptoms 
Fatigue  
Fatigue is reported by over 80% of MS patients [9] and often interferes with family life, work 
or social activities [10]. It is a major determinant of impaired health-related quality of life 
(HRQoL) in MS [11]. Psychometrically validated questionnaires for measuring MS-related 
fatigue are the Fatigue Impact Scale (FIS), the Modified Fatigue Impact Scale (MFIS), and the 
Fatigue Severity Scale (FSS). Treatment options include a management program for a more 
efficient use of energy, progressive resistance training, cognitive behavioral therapy, and 
pharmacotherapy. Drugs that are believed to potentially improve MS-related fatigue are 
amantadine, 4-aminopyridine, 3,4-diaminopyridine, and modafinil. When 6 to 8 weeks after 
start of a drug treatment the patient has not experienced a relevant decrease in fatigue, the 
treatment is discontinued and a different drug is considered.  
Bladder dysfunction 
Symptoms of bladder dysfunction are uncommon at presentation but frequently develop in 
the course of the disease, and are often associated with spastic paraparesis and sexual 
problems [5]. The increased urge and voiding frequency result from detrusor muscle over-
activity and detrusor-sphincter dyssynergia. Urinary tract infections, resulting from 
incomplete bladder emptying, are a frequent complication and may lead to worsening of MS 
symptoms. A 3-day Voiding Diary, the Urinary Distress Inventory (UDI-6) and the 
Incontinence Impact Questionnaire (IIQ-7) are validated tools to comprehensively assess 
bladder dysfunction in MS. Pharmacotherapeutic options include anticholinergics, 
cannabinoids and botulinum toxin.  
Anxiety and depression  
Anxiety and depression are increasingly being recognized as frequent symptoms in MS and 
as a major determinant of worsened HRQoL [11]. The Hospital Anxiety and Depression 
Scale (HADS) questionnaire is a validated assessment tool. In daily practice anxiety 
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disorders, and to a lesser degree depression, are often under-diagnosed in MS patients. As a 
consequence, patients are deprived of psychological and pharmacological treatments that 
might be effective in reducing symptoms and disease burden.      
Cognitive impairment  
Cognitive disturbances are a prominent feature of MS, occurring in about half of all patients 
[12] and in one third of patients with early RRMS [13]. The most frequently impaired 
domains are complex attention, information processing speed, and memory and executive 
functions. MS patients with problems in cognitive performance have increased odds of 
becoming unemployed [12]. Importantly, cognitive symptoms in early RRMS are predictive 
of disability several years later [14], and in benign RRMS failure on neuropsychological tests 
predicts clinical worsening over a 3-year period [15].   
The detection of cognitive impairment in a RRMS patient is a reason to evaluate the current 
policy. Routine evaluation of cognition is useful for helping patients to address ensuing 
problems and to detect cognitive decline as a sign of disease progression or treatment failure 
[16]. Two neuropsychological test batteries have been developed for use in MS patients, the 
Brief Repeatable Neuropsychological Battery (BRNB) and the Minimal Assessment of 
Cognitive Functioning in Multiple Sclerosis (MACFIMS) [for brief descriptions see reference 
17]. The high rater and patient burden (the MACFIMS taking around 90 minutes to 
administer) and the high degree of expertise needed to administer, seriously limit the utility 
of BRNB and MACFIMS in patient care and clinical trials [17]. A recent study reported the 
preliminary validation of a brief computerized cognitive battery in RRMS  [17]. Previous 
data supported the reliability of the Symbol Digit Modalities Test (SDMT) and the Multiple 
Sclerosis Neuropsychological Questionnaire (MSNQ) as potential tools for screening and 
monitoring of cognition in MS [18]. Studies investigating the utility of the SDMT as an 
online test are ongoing. Neuropsychological (memory) training, aiming to improve or 
stabilize cognitive performance, and adjustment of coping strategies are management 
options. Drugs for treatment of cognitive symptoms are under study, although presently no 
pharmacotherapy is available [17]. 
2.4 Disease modifying drugs 
The DMDs exert their effect by modifying immune mechanisms related to the inflammatory 
disease process, and thus prevent demyelination and axonal damage. The first-line DMDs 
INFb and GA combine a moderate efficacy with proven safety, in both the short and the 
long term. In contrast, the highly efficacious DMDs natalizumab, fingolimod and cladribine 
are more likely to have potentially serious side effects on the short term, whereas their long 
term safety still has to be established. The ongoing debate on the optimal use of the DMDs 
in RRMS patients directly relates to their perceived benefits and risks. 
In the escalating treatment approach naïve patients are first prescribed a moderately 
efficacious DMD, and in case of an insufficient response the drug is discontinued and a 
more potent DMD is started. This step-wise regimen is deemed appropriate in patients with 
low disability and a favorable prognosis. The alternative induction regimen is considered in 
treatment-naïve patients who, in spite of a short disease duration, already have acquired 
permanent neurological deficits due to frequent or severe relapses, and with a poor 
prognosis. The aim is to induce a substantial and long-lasting reduction in disease activity, 
in order that future relapses can be prevented by a moderately efficacious DMD. The 
inductive effects of the immunosuppressive agents mitoxantrone and cyclophosphamide 
www.intechopen.com
 
E-Health 2.0 Developments in Treatment and Research in Multiple Sclerosis 
 
461 
have been studied in clinical trials. Natalizumab is, strictly speaking, not an inductive agent, 
as it’s discontinuation is followed by a reappearance of disease activity.                  
In either scenario, escalation or induction, there is a need to closely monitor disease activity, 
in order to prevent further increase in disability (escalation regimen) or unnecessary risk of 
serious side effects (induction regimen).    
2.5 Concept of (very) early treatment 
Pathological findings indicate that inflammation occurring early in the disease leads to 
axonal damage and permanent tissue loss. These histological changes are in due course 
mirrored by the appearance of permanent T1-weighed hypo-intense lesions, and brain and 
spinal cord atrophy on MRI. Recent epidemiological data indicate that as soon as a disability 
level of Expanded Disability Status Score (EDSS) 3 or 4 has been reached, the increase in 
disability during the further course of the disease no longer relates to relapses or treatment 
with DMDs. Interestingly, observational data indicate that start of DMD treatment within 24 
months of disease onset, and even more so in the first 12 months, is associated with less 
long-term disability, later transgression to SPMS and a slower progression during SPMS. 
The concept of (very) early DMD treatment is based on these and related studies and 
proposes to start treatment after the first episode, including CIS, or at least in the first 12 to 
24 months. However, the disease course and accrual of disability is highly variable between 
patients. So, in order not to unnecessarily treat patients who would have a benign course 
without treatment, the (very) early use of DMDs is restricted to those patients in whom 
prognostic features are unfavorable.  
2.6 Prognostic features 
There is a body of evidence suggesting that to a certain degree the short-term disease course 
can be predicted from the presence or absence of specific clinical, MRI and CSF findings. 
However, the methodological limitations of the investigations on the predictive value of 
parameters with respect to the long-term disability make that in individual patients a formal 
prognosis cannot be established. Yet, a comprehensive appraisal of the available patient data 
might justify an ‘educated guess’ on a patient’s prospects, especially for the short term.  
The following clinical characteristics of a first RRMS episode or of CIS are considered 
prognostically unfavorable: multifocal symptoms, pyramidal, cerebellar, or sphincter 
symptoms, need of steroid treatment, and incomplete recovery. In patients with two or more 
relapses a short interval between the first and the second attack is unfavorable, as is the 
occurrence of three or more relapses in the first three years. Some abnormalities suggestive 
of MS on diagnostic MRI also have a prognostic relevance: the occurrence of three or more 
T2-weighed hyper-intense lesions, two or more infra-tentorial lesions, corpus callosum 
lesions, cortical lesions, diffuse lesions in the cervical spinal cord, cerebral or cervical spinal 
cord atrophy, T1-weighed hypo-intense lesions, and one or more gadolinium-enhancing 
lesions. Finally, the presence of immunoglobuline G oligoclonal bands (IgG-OCB), 
intrathecal immunoglobulin M (IgM) synthesis, and a high concentration of light chain 
neurofilament on CSF analyses have also been associated with a less favorable course.                  
2.7 Therapeutic goals 
Conventional clinical measures of the effectiveness of DMD treatment include the number 
and severity of relapses, need of steroid-treatment for relapses, and EDSS or Multiple 
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Sclerosis Functional Composite (MSFC) score (disability). In clinically stable patients new or 
enlarged T2-weighed hyper-intense lesions, new or enlarged T1-weighed hypo-intense 
lesions or gadolinium-enhanced T1- weighed MRI lesions, and (increase of) cerebral or 
spinal cord atrophy all reflect subclinical disease activity. Clinical and MRI parameters may 
be combined into a composite measure of disease activity or disease free status. Thus, in a 
recent study sustained freedom of disease activity was defined as the patient having no 
relapse, no 3-month sustained increase in EDSS, and no new MRI lesions (no T1 
gadolinium-enhancing or new/enlarged T2 lesions) over a specified period [19].  
The ultimate goal of DMD treatment is not only to prevent clinical and MRI disease activity, 
but also the transgression to SPMS. For DMDs to have a maximum chance to obtain this 
long-term goal, treatment should not only be started timely but also managed in such a way 
that EDSS 3 to 4 is not reached. To this end the following short-term clinical and MRI 
measures of disease activity may be monitored: occurrence of a relapse, change in disability 
(EDSS), new or enlarging T2-weighed hyper-intense or T1-weighed hypo-intense lesions, 
gadolinium-enhancing lesions, and (increase of) brain and spinal cord atrophy. It was 
recently found that early EDSS change and medication possession ratio are moderate 
predictors of long-term disability [20] [21]. A higher medication possession ratio predicted 
better long-term clinical outcomes, while greater early increase in EDSS score predicted 
worse outcomes. In contrast, change in MRI parameters were only weakly associated with 
long-term outcome [20]. So, it seems that short-term clinical changes and adherence to DMD 
treatment have a higher prognostic value than MRI measures. The added value of composite 
measures remains to be established.     
3. E-health 2.0 in multiple sclerosis treatment 
The availability of a broad range of DMDs for the treatment of RRMS, the prognostic 
relevance of early disease activity in CIS and RRMS, the prognostic relevance of early 
disease activity after start of treatment, the importance of the timing of treatment initiation, 
the potentially serious side effects of the newer drugs and our ignorance of their long-term 
risks, implicate that in the coming years MS treatment is increasingly being characterized by 
both complexity and personalization. In this context, the use of Web 2.0 techniques for 
interactive online monitoring and care might make a crucial contribution to the management 
of MS patients. Interactive online monitoring and care are believed to enhance the chances that 
the potential benefits of the DMDs are realized and that treatment goals are achieved.   
3.1 Monitoring 
Aspects of monitoring  
Monitoring may be defined as repeated testing aimed at guiding and adjusting the 
management of a chronic or recurrent condition [22]. Minimum criteria for monitoring are 
that clinically significant changes in the condition or effect of treatment occur over time, that 
there is an available monitoring test that reliably detects clinically significant changes when 
they occur, and that cost-effective action can be taken on the basis of the test result [22]. As 
monitoring involves a series of tests over time a monitoring strategy needs to consider 
frequency and timing of tests in the context of a series of sequential results [22]. It should 
address the following questions: Who should be monitored? What outcome should be 
monitored? What test should be used? When, and at what interval? Who should do the 
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monitoring? What action to take on the monitoring result? [23]. Only since the occurrence in 
2005 of progressive multifocal leukencelopathy, a potentially lethal CNS disorder, as a rare 
side effect of natalizumab has monitoring become a topic in MS neurology. As monitoring of 
disease activity and adverse events in DMD-treated patients is a rather recent development, 
most of the fundamental questions regarding the optimal monitoring strategies still have to 
be answered. 
Monitoring in multiple sclerosis  
In view of the nature of the parameters for current or future disease activity mentioned 
above, the conventional monitoring of CIS and RRMS patients focuses on doctor-centered 
clinical and MRI outcomes. In fact, in daily clinical practice the natural course of the disease 
as well as the course after start of DMD treatment is monitored by means of assessments 
during the patients’ regular visits to the out-patient department, with intervals that usually 
vary from 3 to 12 months. Doctors and nurses ask about relevant changes in symptoms, 
notably those suggestive of a relapse or progression, and ideally disability is measured 
using a validated clinical scale, e.g. the EDSS or MSFC. However, in general neurological 
practices the regular and standardized quantification of disability is probably an exception, 
rather than the rule. Moreover, it is doubtful whether CIS and RRMS patients have a T2-
weighed and gadolinium-enhanced T1-weighed brain and spinal MRI scan performed on a 
sufficiently regular basis, given the costs of scanning time and of gadolinium. Importantly, 
practical circumstances, like travel distances and expenses, scarcity of qualified medical 
personnel, and restricted availability of MRI machines, often prevent the conventional 
monitoring process from being optimal, both in terms of the selection of patients, the tests 
used, and the frequency of assessments.  
Monitoring by online self-assessment 
Compared to doctor-centered or technical measures patient-reported outcomes have various 
advantages. Firstly, they have an intrinsic clinical relevance; secondly, data are less 
expensive to acquire; and thirdly, the assessment schedule is more flexible and can easily be 
adjusted to changing circumstances or unexpected outcomes. For example, the frequency of 
assessments can be increased if there is a narrow time window regarding the start of DMD 
treatment, or if a dose increase is associated with a risk of serious side effects. Traditionally, 
patient-reported outcomes are obtained via questionnaires on site, per postal questionnaire 
or per telephone. Prospective well-designed studies in MS patients using patient-reported 
outcomes via the internet are scarce. Yet, especially the web-based applications of accepted 
and validated measures have obvious advantages compared to doctor-centered outcomes 
obtained on site. Online questionnaires and diaries can be completed at home at time points 
convenient to patients; errors and missing data are minimized by instantaneous checks of 
completeness and consistency; and electronic data capture into a database prevents 
transmission errors. Moreover, as online questionnaires are ready available, assessment 
intervals can be short and flexible, and monitoring schedules can easily be tailored to 
individual needs, e.g. for detection of early changes. Finally, patient-centered data may 
provide information that complements or partially substitutes doctor-reported data, 
rendering monitoring less time-consuming for neurologists and MS nurses.   
We investigated in an exploratory manner whether monitoring by online self-assessments 
with monthly intervals is feasible and informative in RRMS patients starting a DMD [24]. 
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We included 167 RRMS patients in a 12-month observational study during which patients 
were asked to complete two short questionnaires, on HRQoL and fatigue, at monthly 
intervals. 73.7% completed both questionnaires at all 13 time points, whereas 85.1% of the 
patients completed both questionnaires in at least 7 of the 13 time points. For both 
questionnaires the mean changes between baseline and month 12 were similar to those 
found in studies using paper questionnaires completed on site or at home with 6-month 
intervals. These data indicate the feasibility and potential usefulness of monitoring by 
monthly online self-assessment. Intensive online monitoring appears to be an informative 
and patient-friendly tool for assessing short-term effectiveness. It can be argued that the full 
advantages of monitoring by online self-assessment are only realized in the context of an 
interactive care setting.     
3.2 Treatment and care 
In the past two decades the expanding knowledge on the inflammatory mechanisms leading 
to tissue damage in MS and the pathophysiological changes underlying the major symptoms 
have initiated a plethora of therapeutic studies, varying from placebo-controlled 
randomized trials to observational studies and anecdotal reports. Study data have given 
neurologists and MS-nurses ample opportunities to substantially lessen the disease burden 
in their patients. However, it is recognized that as yet most patients insufficiently benefit 
from the insights and therapeutic potential generated by research data [25]. The unmet 
needs in MS patients relate to the fact that the implementation of treatment options is 
hampered by limited resources and organizational insufficiencies and inefficiencies. One of 
the measures to improve both effectiveness and efficiency of MS care may be the 
introduction of Web 2.0 applications in the care process. 
Interactive online care 
To outline the potential advantages of interactive online care in MS patients a typical 
example, the MSmonitor project, is described here. This project aims to improve MS care in 
the Netherlands by interactive use of the internet on the basis of patient-reported outcomes, 
obtained via online self-assessment. MSmonitor started in 2010 and at present 12 MS centers 
and neurological practices participate. Basically, every six months patients complete the 
Multiple Sclerosis Impact Profile (MSIP) and the Multiple Sclerosis Quality of Life-54 
(MSQoL-54) or the Leeds Multiple Sclerosis Quality of Life (LMSQoL) scale online 1 to 2 
weeks before their regular out-patient visit.  
The MSIP is a psychometrically validated outcome measure for disability and disability 
perception in MS patients [26]. The scale is based on the International Classification of 
Functioning, Disability and Health (ICF) of the World Health Organization (WHO). The 
MSIP disability data are complementary to the doctor-centered EDSS. In those neurological 
practices where the EDSS cannot be assessed (time constraints,  lack of qualified personnel) 
the MSIP disability data may provide a validated patient-reported alternative. In addition, 
the disability perception part of the MSIP informs on the subjective dimension of symptoms 
and signs and provides a systematic, complete, detailed, and quantitative overview of 
experienced burden of disease. In the online application of the MSIP answers that represent 
a worsening compared to the previous assessment are automatically highlighted. Thus, the 
online MSIP gives a quick screen of both the current condition and of recent changes. The 
individual data are made available on the secured project website to treating MS-nurse and 
neurologist, and helps them to prepare the on site consultation. In fact, the MSIP overview 
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may guide the conversation between patient and MS-nurse or neurologist, by focusing on 
changes with high disability perception. The inventory of symptoms according to relevance 
and the preview opportunity for caregivers are thought to enhance effectiveness and 
efficiency of outpatient visits.  
The MSQoL-54 and the LMSQoL measure HRQoL. HRQoL is a multidimensional concept 
related to a person’s perception of well-being and the level of role fulfillment across a range 
of dimensions, including physical, psychosocial, social and symptom-related dimensions 
[27]. It is a term that refers to an individual’s assessment of how a health problem as well as 
its treatment affect his/her ability to perform activities and roles that he/she values [28]. A 
critical element of HRQoL is that it reflects the patient's assessment of the impact of his/her 
illness, not the physician's perspective, as most physiologically oriented measures and 
traditional clinical scales do [29]. As HRQoL comprises not only perceptions of physical 
functioning and general health, but also perceived psychological functioning and social/role 
functioning [30], its assessment is thought to provide a comprehensive evaluation of an 
individual’s health [31]. Using the MSIP it was demonstrated that HRQoL impairment in 
MS patients was most related to emotional problems, cognitive dysfunction, and sleep 
disturbances [26]. In DMD-treated patients the HRQoL data help to assess the treatment’s 
overall effectiveness from the patient’s perspective [32] [33]. 
In addition to the 6-monthly assessments, MS-nurse and neurologist may in selected 
patients activate these scales at additional time points or activate symptom-related 
questionnaires for in-depth assessment of specific symptoms, e.g. when a subjective 
worsening has been reported by e-mail or by phone; or to obtain valid pre-treatment values 
by repeated measurements; or to closely follow initial changes after start of treatment; or to 
evaluate specific treatment effects. An example: the beneficial effect of symptomatic drug 
treatment of MS-related fatigue usually manifests itself within 6 to 8 weeks. The low chance 
of a relevant change in fatigue and the possibility of side effects urge a timely evaluation. 
The repeated online use of the MFIS informs on the baseline condition and the degree of 
short-term change in MS-related fatigue. Other symptoms can also be quantified online by 
symptom-specific validated questionnaires, such as depression and anxiety by the HADS, 
bladder symptoms by a Voiding Diary, and comorbidity by the Self-Report Comorbidity 
Questionnaire for Multiple Sclerosis (SRCQ-MS). The SDMT may be included for 
assessment of cognition, as soon as preliminary data on an the validity of the online version 
have been confirmed.  
The combination of the instantaneous availability of patient-reported outcomes on 
disability, disability perception and symptoms prior to and during out-patient visits, the 
possibility of repeated assessments and of symptom-related in–depth measurements,  the 
online evaluation by caregivers via the secured website, and the flexible feedback by short-
message service (SMS) or e-email  has the potential to improve effectiveness and efficiency 
of MS treatment and care. Moreover, an outcome value that represents a clinically 
minimally important change may be set as an alert level. As soon as the outcome variable 
reaches the predefined limit an alert pops up on the screen, a message is sent by e-mail to 
the neurologist or MS-nurse, or appears on their screen after log in, whatever is decided. 
E.g. patients with a tendency to depressive symptoms who start INFb treatment may use the 
online HADS for monitoring mood with a predefined alert set-point. Preliminary data from 
the MSmonitor project indicate that the use of Web 2.0 technology in MS care benefits both 
patient and caregiver in terms of flexibility and efficiency, as self-assessment, evaluation, 
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and feedback do not depend on consulting hours or simultaneous availability of patient and 
caregiver. A next step will be the development of an interactive education program for 
patients and caregivers.       
4. E-health 2.0 in multiple sclerosis research  
4.1 Web-based phase IV research 
Randomized placebo-controlled phase II/III trials provide data on a DMD’s efficacy to 
reduce in the short term the frequency and severity of the clinical manifestations of 
inflammation (relapses) and of surrogate parameters (MRI lesions). Such trials do not 
inform on the long-term efficacy, in terms of preventing disability increase or conversion to 
SPMS, or slowing progression during SPMS; nor on long-term side effects. It is also of note 
that in fact  the phase II/III results do not pertain to patients treated in real life, as data are 
typically obtained from selected patients, treated in dedicated MS centers in large, often 
academic hospitals.   
Data on the long-term effectiveness and safety in patients treated in daily practice can be 
acquired in observational phase IV studies, and the internet enables virtually every  
MS patient to participate in such studies. Within the framework of a prospective 
observational study every patient who starts a treatment can be asked to regularly 
complete online a set of standard questions concerning aspects of effectiveness and side 
effects. In a web-based study a patient’s participation does not depend on his/her 
geographic location or distance to out-patient clinic, and therefore an online study may 
include large cohorts in whole regions or even countries. Methodologically, the 
representative character of the online acquired data enables the external validation of the 
phase III data. As to drug safety, an online observational study covering a whole 
population or region with virtually no restrictive selection criteria yields an almost 
complete picture of adverse events in real life. 
4.2 Interactive observational research 
An important aspect of web-based phase IV research is that study data on effectiveness and 
safety from individual patients can be made available to treating MS-nurse or neurologist 
for monitoring purposes. We started in the Netherlands the Dutch MS Study, a prospective, 
online, patient-centred study of long-term disability, disability perception and HRQoL in 
patients with MS or CIS. Every 6 months patients complete the MSIP (disability and 
disability perception) and the MSQoL-54 (HRQoL). Disease characteristics and 
demographic, diagnostic and medication data are recorded online at the start of a patient’s 
participation, and thereafter relapses and medication use can be updated every month. A 
patient may consent to give his/her MS-nurse or neurologist access to the study data for 
evaluation of treatment or the natural course of the disease. Actually, as the information 
provided by the study data may lead to an adjustment of the disease management, e.g. 
discontinuation or change of medication, we have created a setting in which there is an 
interaction between observation and daily practice. As a result, the study data may give 
insight not only into factors that relate to changes in the disease course, but also in those that 
drive the decisions regarding treatment and care processes.   
The study’s inclusion criteria are: having the diagnosis MS or CIS, and being willing and 
able to participate in the investigations. The latter criterion implies the availability of a 
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computer for online access. In fact, as almost  every patient with MS or CIS is eligible the 
Dutch MS study is developing into an interactive Dutch MS registry.  
4.3 Adherence and adherence research 
The effectiveness of DMD treatment depends on adequate adherence and implies year-long 
continued drug administration with a minimum of missed doses. The two aspects of 
inadequate adherence are: 1) missing doses, and 2) early discontinuation for other reason 
than insufficient response, serious side effects or persistent moderate side effects. Patients 
treated with the injectable first-line DMDs miss 30% of the doses [34], and the 6-month 
discontinuation rate may be as high as 27% [35]. It has been known that DMD 
discontinuation for more than three months is associated with a increased risk of relapses. 
Recent data show that in RRMS patients the degree of disability eight years after start of 
INFb-1a treatment is related to the medication possession ratio [21] Adherence is influenced 
by the socio-economic situation, health care and caregivers, disease, treatment and patient 
characteristics. In MS patients self-efficacy expectations are thought to be related to 
adherence, as are patient education and optimal support. A detailed knowledge of those 
aspects of care that significantly relate to adherence may lead to adherence-improving 
measures. Moreover, the identification of patients at high risk of inadequate adherence 
could lead to more efficient care.  
The CAIR (Correlative analyses of Adherence In Relapsing remitting multiple sclerosis) 
study investigates in GA-treated RRMS patients the relationship between drug adherence 
and multidisciplinary care, as well as factors associated with adherence [36]. The study is a 
prospective, web-based, patient-centered, nation-wide, observational cohort study in the 
Netherlands. The primary objective is to investigate whether adherence is associated with 
specific disciplines of care or quantities of specific care. The secondary objective is to 
investigate whether adherence is associated with specific aspects of the socio-economic 
situation, health care and caregivers, disease, treatment or patient characteristics. 
All data are acquired online via a study website (www.cairstudie.nl) and all RRMS patients 
in the Netherlands starting GA treatment were eligible. At pre-defined and random time-
points patients are requested to complete a short questionnaire on missed doses and 
eventual discontinuation. Every two weeks patients record the care they received 
(discipline, frequency, duration). The Dutch Adherence Questionnaire-90 (DAQ-90), a 90-
item questionnaire based on the World Health Organization (WHO) 2003 report on 
adherence, comprehensively assesses the five domains of evidence-based determinants of 
adherence: socio-economic, health care and caregivers, disease, treatment, and patient-
related factors. Self-efficacy is assessed by the Multiple Sclerosis Self-Efficacy Scale (MSSES), 
and mood and HRQoL by the MSQoL-54.  
Importantly, adherence data from online self-assessment can be used in an interactive web-
based care setting, like the MSmonitor project. Access to individual data enables neurologist 
and MS-nurse to monitor adherence, whereas the regular completion of a short 
questionnaire may per se be an adherence promoting activity. Based on the online  data 
caregivers will be able to give feedback to patients with inadequate adherence, whereas the 
choice of adherence improving measures can be guided by the pre-treatment online 
inventory of risk factors (DAQ-90). It is expected that in the near future online monitoring of 
adherence and interactive web-based care, tailored to the individual risk factors, may help 
to improve adherence and thus the effectiveness of DMD treatments.        
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4.4 Patient empowerment 
The interactive use of the internet for monitoring and care purposes enables patients to 
better understand and evaluate their own conditions. As a result, patients become educated 
partners in the relation with caregivers and may take initiatives as to how their MS should 
be managed. Interactive programs that inform and educate on treatment options, e.g. using 
evidence-based algorithms, will help patients to position themselves as independent actors 
in the process of benefit-to-risk evaluation and shared decision making. As the Web 2.0 
technology is likely to increase knowledge and awareness in many individual patients, it 
may thus collectively transform web-based patient communities into grassroots movements 
that initiate and drive research projects on topics that are relevant to patients but do not 
appeal to pharmaceutical companies and academia.  
5. Conclusion 
Current developments suggest that in the coming years Web 2.0 technologies will be 
integrated in the treatment and care of MS patients and in MS research. Monitoring of 
effectiveness, safety and adherence by online self-assessment is the basis of interactive 
online care and (interactive) observational phase IV research. E-health 2.0 developments are 
likely to increase patients’ empowerment and will favor patient-driven decision making and 
research. In the context of ever diminishing health care resources and an increasing 
likelihood of drastic changes in the health care system, for MS patients e-health 2.0 could 
make the difference between, on the one hand, an ongoing suboptimal use of ever more 
efficacious drugs with persistence of unmet needs, and, on the other hand, personalized, 
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